Roche says Alecensa more effective than rival drug in lung cancer

Roche said that its kinase inhibitor Alecensa (alectinib) has produced better results in a Phase 3 trial of patients with a specific type of lung cancer than a rival treatment marketed by Pfizer Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.